- Home
- ETON vs DSM Comparison
ETON vs DSM Comparison
Compare ETON & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- DSM
- Stock Information
- Founded
- ETON 2017
- DSM 1989
- Country
- ETON United States
- DSM United States
- Employees
- ETON N/A
- DSM N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- DSM Investment Managers
- Sector
- ETON Health Care
- DSM Finance
- Exchange
- ETON Nasdaq
- DSM Nasdaq
- Market Cap
- ETON 329.8M
- DSM 270.9M
- IPO Year
- ETON 2018
- DSM N/A
- Fundamental
- Price
- ETON $14.55
- DSM $5.42
- Analyst Decision
- ETON Strong Buy
- DSM
- Analyst Count
- ETON 3
- DSM 0
- Target Price
- ETON $27.67
- DSM N/A
- AVG Volume (30 Days)
- ETON 235.8K
- DSM 161.7K
- Earning Date
- ETON 05-08-2025
- DSM 01-01-0001
- Dividend Yield
- ETON N/A
- DSM 3.97%
- EPS Growth
- ETON N/A
- DSM N/A
- EPS
- ETON N/A
- DSM N/A
- Revenue
- ETON $39,011,000.00
- DSM N/A
- Revenue This Year
- ETON $92.33
- DSM N/A
- Revenue Next Year
- ETON $52.62
- DSM N/A
- P/E Ratio
- ETON N/A
- DSM N/A
- Revenue Growth
- ETON 23.29
- DSM N/A
- 52 Week Low
- ETON $3.11
- DSM $4.69
- 52 Week High
- ETON $18.41
- DSM $6.05
- Technical
- Relative Strength Index (RSI)
- ETON 57.21
- DSM 32.63
- Support Level
- ETON $13.53
- DSM $5.40
- Resistance Level
- ETON $14.40
- DSM $5.77
- Average True Range (ATR)
- ETON 0.97
- DSM 0.10
- MACD
- ETON 0.32
- DSM -0.01
- Stochastic Oscillator
- ETON 96.19
- DSM 22.13
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.